United States (US) Candidemia Market (2025-2031) | Competitive Landscape, Size & Revenue, Analysis, Forecast, Value, Growth, Trends, Industry, Outlook, Segmentation, Share, Companies

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3.1 United States (US) Country Macro Economic Indicators

3.2 United States (US) Candidemia Market Revenues & Volume, 2021 & 2031F

3.3 United States (US) Candidemia Market - Industry Life Cycle

3.4 United States (US) Candidemia Market - Porter's Five Forces

3.5 United States (US) Candidemia Market Revenues & Volume Share, By Drugs, 2021 & 2031F

4.1 Impact Analysis

4.2 Market Drivers

4.2.1 Increasing prevalence of candidemia infections in the US due to factors such as aging population, rising number of immunocompromised individuals, and higher incidence of invasive medical procedures.

4.2.2 Growing awareness among healthcare providers about the importance of early detection and treatment of candidemia.

4.2.3 Technological advancements in diagnostic methods and treatment options for candidemia leading to improved patient outcomes.

4.3 Market Restraints

4.3.1 High cost associated with the diagnosis and treatment of candidemia may limit access to care for some patients.

4.3.2 Antibiotic resistance leading to challenges in effectively treating candidemia infections.

4.3.3 Stringent regulatory requirements for the approval of new antifungal drugs may slow down the introduction of innovative therapies.

6.1 United States (US) Candidemia Market, By Drugs

6.1.1 Overview and Analysis

6.1.2 United States (US) Candidemia Market Revenues & Volume, By Drugs, 2021- 2031F

6.1.3 United States (US) Candidemia Market Revenues & Volume, By Rezafungin (Ezafungin acetate), 2021- 2031F

6.1.4 United States (US) Candidemia Market Revenues & Volume, By Eraxis (Anidulafungin), 2021- 2031F

6.1.5 United States (US) Candidemia Market Revenues & Volume, By Cancidas (Caspofungin), 2021- 2031F

6.1.6 United States (US) Candidemia Market Revenues & Volume, By Diflucan (Fluconazole), 2021- 2031F

6.1.7 United States (US) Candidemia Market Revenues & Volume, By Vfend (Voriconazole), 2021- 2031F

6.1.8 United States (US) Candidemia Market Revenues & Volume, By Fosmanogepix, 2021- 2031F

7.1 United States (US) Candidemia Market Export to Major Countries

7.2 United States (US) Candidemia Market Imports from Major Countries

8.1 Average length of hospital stay for candidemia patients in the US.

8.2 Mortality rate of candidemia cases in the US.

8.3 Rate of adoption of new diagnostic tools and treatment modalities for candidemia in healthcare facilities.

8.4 Percentage of candidemia cases with timely initiation of appropriate antifungal therapy.

8.5 Number of research studies and clinical trials focused on candidemia treatment and management in the US.

9.1 United States (US) Candidemia Market Opportunity Assessment, By Drugs, 2021 & 2031F

10.1 United States (US) Candidemia Market Revenue Share, By Companies, 2024

10.2 United States (US) Candidemia Market Competitive Benchmarking, By Operating and Technical Parameters